tru Independence LLC raised its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 27,816 shares of the company's stock after buying an additional 85 shares during the quarter. tru Independence LLC's holdings in Johnson & Johnson were worth $4,543,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in JNJ. DORCHESTER WEALTH MANAGEMENT Co boosted its position in shares of Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company's stock valued at $14,975,000 after purchasing an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P boosted its position in shares of Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company's stock valued at $31,049,000 after purchasing an additional 82,429 shares in the last quarter. AMI Investment Management Inc. boosted its position in shares of Johnson & Johnson by 8.8% during the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company's stock valued at $3,244,000 after purchasing an additional 1,475 shares in the last quarter. Equitable Holdings Inc. boosted its position in shares of Johnson & Johnson by 4.9% during the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company's stock valued at $8,095,000 after purchasing an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd boosted its position in shares of Johnson & Johnson by 2.4% during the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company's stock valued at $152,488,000 after purchasing an additional 20,528 shares in the last quarter. 67.94% of the stock is currently owned by institutional investors.
Get
Johnson & Johnson alerts:
Insider Activity at Johnson & Johnson
In related news, EVP Jennifer L. Taubert sold 76,923 shares of the company's stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares in the company, valued at $22,354,891.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the business's stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the sale, the chief financial officer now owns 35,812 shares of the company's stock, valued at $6,431,835.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 76,923 shares of the business's stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the sale, the executive vice president now directly owns 126,456 shares of the company's stock, valued at approximately $22,354,891.68. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 233,611 shares of company stock worth $40,960,735. 0.35% of the stock is owned by insiders.
Johnson & Johnson Stock Down 0.4 %
JNJ stock opened at $168.23 on Friday. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The business has a fifty day moving average price of $175.63 and a 200-day moving average price of $170.96. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The stock has a market capitalization of $439.83 billion, a P/E ratio of 24.96, a P/E/G ratio of 2.91 and a beta of 0.56.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.13. The firm had revenue of $23.71 billion during the quarter, compared to analysts' expectations of $23.90 billion. Johnson & Johnson had a return on equity of 35.94% and a net margin of 18.90%. The company's revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.13 earnings per share. Equities analysts forecast that Johnson & Johnson will post 10.52 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date is Friday, February 17th. Johnson & Johnson's dividend payout ratio (DPR) is presently 67.06%.
Analyst Ratings Changes
Several equities research analysts recently weighed in on the company. Credit Suisse Group assumed coverage on Johnson & Johnson in a research report on Thursday, November 17th. They set a "neutral" rating and a $170.00 price target on the stock. Sanford C. Bernstein dropped their target price on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Morgan Stanley boosted their target price on Johnson & Johnson from $176.00 to $180.00 and gave the stock an "equal weight" rating in a report on Wednesday. SVB Leerink dropped their target price on Johnson & Johnson from $194.00 to $186.00 and set an "outperform" rating on the stock in a report on Friday, January 20th. Finally, Barclays started coverage on Johnson & Johnson in a report on Monday, October 17th. They issued an "equal weight" rating and a $175.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average target price of $182.75.
About Johnson & Johnson
(Get Rating)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets.
Further Reading
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
